Hostname: page-component-89b8bd64d-n8gtw Total loading time: 0 Render date: 2026-05-07T05:20:46.655Z Has data issue: false hasContentIssue false

Surveillance of SARS-CoV-2 prevalence from repeated pooled testing: application to Swiss routine data

Published online by Cambridge University Press:  22 August 2024

Julien Riou*
Affiliation:
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland Department of Epidemiology and Health Systems, Unisanté, Center for Primary Care and Public Health & University of Lausanne, Lausanne, Switzerland
Erik Studer
Affiliation:
Federal Office of Public Health, Liebefeld, Switzerland
Anna Fesser
Affiliation:
Federal Office of Public Health, Liebefeld, Switzerland
Tobias Magnus Schuster
Affiliation:
Federal Office of Public Health, Liebefeld, Switzerland
Nicola Low
Affiliation:
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Matthias Egger
Affiliation:
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
Anthony Hauser
Affiliation:
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris, France
*
Corresponding author: Julien Riou; Email: julien.riou@unisante.ch
Rights & Permissions [Opens in a new window]

Abstract

Surveillance of SARS-CoV-2 through reported positive RT-PCR tests is biased due to non-random testing. Prevalence estimation in population-based samples corrects for this bias. Within this context, the pooled testing design offers many advantages, but several challenges remain with regards to the analysis of such data. We developed a Bayesian model aimed at estimating the prevalence of infection from repeated pooled testing data while (i) correcting for test sensitivity; (ii) propagating the uncertainty in test sensitivity; and (iii) including correlation over time and space. We validated the model in simulated scenarios, showing that the model is reliable when the sample size is at least 500, the pool size below 20, and the true prevalence below 5%. We applied the model to 1.49 million pooled tests collected in Switzerland in 2021–2022 in schools, care centres, and workplaces. We identified similar dynamics in all three settings, with prevalence peaking at 4–5% during winter 2022. We also identified differences across regions. Prevalence estimates in schools were correlated with reported cases, hospitalizations, and deaths (coefficient 0.84 to 0.90). We conclude that in many practical situations, the pooled test design is a reliable and affordable alternative for the surveillance of SARS-CoV-2 and other viruses.

Information

Type
Original Paper
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - SA
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (http://creativecommons.org/licenses/by-nc-sa/4.0), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is used to distribute the re-used or adapted article and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use.
Copyright
© The Author(s), 2024. Published by Cambridge University Press
Figure 0

Figure 1. Simulation study (a) Three scenarios of prevalence over time were used to simulate pooled test data. The dashed line shows the overall prevalence, and the circles show the prevalence values across five subareas. (b) Example of model fit to scenario 3 for the naive model and the Gaussian process (GP) model. (c) Root mean squared error (RMSE) measuring the accuracy of prevalence estimates obtained from the naive model or the GP model (lower values are better), for each combination of pool size $ P $ (5, 10, or 20) and total sample size $ N $ (100, 500, 1,000, or 5,000). (d) Half-width of the 95% credible interval measuring the sharpness of prevalence estimates obtained from the naive model or the GP model (lower values are better). (e) RMSE of prevalence estimates obtained from the naive model or the GP model according to the population prevalence (<2%, 2–5%, and 5–10%).

Figure 1

Table 1. Pooled test data collected for monitoring SARS-CoV-2 in Switzerland between 19 April 2021 and 29 August 2022

Figure 2

Figure 2. Pooled test data collected for monitoring SARS-CoV-2 in Switzerland between 19 April 2021 and 29 August 2022 in three types of setting (schools, care centres, and selected workplaces): (a) the total number of pools per week (truncated at 20); (b) distribution of the pool size (cut at 30); and (c) proportion of positive pools over time (the line corresponds to weekly average).

Figure 3

Figure 3. SARS-CoV-2 prevalence estimated from pooled test data in Switzerland between 19 April 2021 and 29 August 2022 in three settings: schools (panel a), care centres (panel b), and selected workplaces (panel c). The lines represent the posterior means, and the coloured areas the 95% credible intervals. The white bars show the weekly number of reported cases of SARS-CoV-2 infections in corresponding age groups scaled by population (0–20 for schools, above 60 for care centres, and 21–60 for selected workplaces).

Figure 4

Figure 4. (a) Absolute difference (with 95% credible interval) in SARS-CoV-2 prevalence estimated from pooled test data at the national level across settings (selected workplaces are taken as the reference). (b) SARS-CoV-2 prevalence estimated from pooled test data in six regions of Switzerland between 19 April 2021 and 29 August 2022 in three settings (vertical dotted lines indicate the period used in panel C). (c) Mean prevalence estimated from pooled test data in schools at the regional level between 1 January and 31 March 2022 (Ticino is excluded).

Figure 5

Table 2. Correlation between SARS-CoV-2 prevalence estimated from pooled test data and other indicators of the dynamics of SARS-CoV-2 in Switzerland (Spearman’s rank correlation coefficient with 95% credible interval)